Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 1, 2012, Pages 165-174

  Barrick, Cordelia J ^a   Lenhart, Patricia M ^a   Dackor, Ryan T ^a   Nagle, Elizabeth ^a   Caron, Kathleen M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adrenomedullin; Cardiovascular disease; Heart failure; Hypertension; Receptor activity modifying proteins; Sex differences

Indexed keywords

ANGIOTENSIN II; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GENE; GENE EXPRESSION; GENE LOSS; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY DYSFUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR ACTIVITY MODIFYING PROTEIN 3 GENE; SEX DIFFERENCE; UPREGULATION;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; GENETIC ASSOCIATION STUDIES; HEART FAILURE; HYPERTENSION; HYPERTROPHY, RIGHT VENTRICULAR; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR ACTIVITY-MODIFYING PROTEIN 3; RENIN; SEX FACTORS;

MUS;

EID: 84155186325     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.10.021     Document Type: Article

References (63)

1. Regitz-Zagrosek V., Lehmkuhl E. Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. Herz Aug. 2005, 30(5):356-367.
2. Babiker F.A., Lips D., Meyer R., Delvaux E., Zandberg P., Janssen B., et al. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol Jul. 2006, 26(7):1524-1530.
3. Huang A., Kaley G. Gender-specific regulation of cardiovascular function: estrogen as key player. Microcirculation Jan-Feb. 2004, 11(1):9-38.
4. Patten R.D., Pourati I., Aronovitz M.J., Baur J., Celestin F., Chen X., et al. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004, 95(7):692-699.
5. Satoh M., Matter C.M., Ogita H., Takeshita K., Wang C.Y., Dorn G.W., et al. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 2007, 115(25):3197-3204.
6. Skavdahl M., Steenbergen C., Clark J., Myers P., Demianenko T., Mao L., et al. Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 2005, 288(2):H469-H476.
7. Hsia J., Criqui M.H., Herrington D.M., Manson J.E., Wu L., Heckbert S.R., et al. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am Heart J 2006, 152(1):170-176.
8. Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2(3):228-239.
9. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
10. Murphy E., Lagranha C., Deschamps A., Kohr M., Nguyen T., Wong R., et al. Mechanism of cardioprotection: what can we learn from females?. Pediatr Cardiol 2011, 32(3):354-359.
11. Yang X.P., Reckelhoff J.F. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 2011, 20(2):133-138.
12. Adlbrecht C., Hulsmann M., Strunk G., Berger R., Mortl D., Struck J., et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009, 11(4):361-366.
13. Al-Omari M.A., Khaleghi M., Mosley T.H., Turner S.T., Morgenthaler N.G., Struck J., et al. Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension. Am J Hypertens 2009, 22(8):860-866.
14. Khan S.Q., O'Brien R.J., Struck J., Quinn P., Morgenthaler N., Squire I., et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007, 49(14):1525-1532.
15. von Haehling S., Filippatos G.S., Papassotiriou J., Cicoira M., Jankowska E.A., Doehner W., et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010, 12(5):484-491.
16. Ishimitsu T., Ono H., Minami J., Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006, 111(3):909-927.
17. Kato K., Yin H., Agata J., Yoshida H., Chao L., Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003, 285(4):H1506-H1514.
18. Nagaya N., Satoh T., Nishikimi T., Uematsu M., Furuichi S., Sakamaki F., et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000, 101(5):498-503.
19. Nishikimi T., Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents 2005, 3(3):231-242.
20. Okumura H., Nagaya N., Kangawa K. Adrenomedullin infusion during ischemia/reperfusion attenuates left ventricular remodeling and myocardial fibrosis in rats. Hypertens Res 2003, 26(Suppl):S99-S104.
21. Tokudome T., Horio T., Yoshihara F., Suga S., Kawano Y., Kohno M., et al. Adrenomedullin inhibits doxorubicin-induced cultured rat cardiac myocyte apoptosis via a cAMP-dependent mechanism. Endocrinology 2002, 143(9):3515-3521.
22. Yin H., Chao L., Chao J. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension 2004, 43(1):109-116.
23. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393(6683):333-339.
24. Morfis M., Christopoulos A., Sexton P.M. RAMPs: 5 years on, where to now?. Trends Pharmacol Sci 2003, 24(11):596-601.
25. Dackor R., Fritz-Six K., Smithies O., Caron K. Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem 2007, 282(25):18094-18099.
26. Fritz-Six K.L., Dunworth W.P., Li M., Caron K.M. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest Jan. 2008, 118(1):40-50.
27. Wootten D.L., Simms J., Hay D.L., Christopoulos A., Sexton P.M. Receptor activity modifying proteins and their potential as drug targets. Prog Mol Biol Transl Sci 2010, 91:53-79.
28. Cueille C., Pidoux E., de Vernejoul M.C., Ventura-Clapier R., Garel J.M. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. Biochem Biophys Res Commun Jun 7 2002, 294(2):340-346.
29. Oie E., Vinge L.E., Andersen G.O., Yndestad A., Krobert K.A., Sandberg C., et al. RAMP2 and RAMP3 mRNA levels are increased in failing rat cardiomyocytes and associated with increased responsiveness to adrenomedullin. J Mol Cell Cardiol Jan. 2005, 38(1):145-151.
30. Yoshihara F., Nishikimi T., Okano I., Hino J., Horio T., Tokudome T., et al. Upregulation of intracardiac adrenomedullin and its receptor system in rats with volume overload-induced cardiac hypertrophy. Regul Pept Apr. 15 2005, 127(1-3):239-244.
31. Nishikimi T., Tadokoro K., Mori Y., Wang X., Akimoto K., Yoshihara F., et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension Mar. 2003, 41(3):512-518.
32. Pan Ch S., Jiang W., Wu Sh Y., Zhao J., Pang Y.Z., Tang Ch S., et al. Potentiated response to adrenomedullin in myocardia and aortas in spontaneously hypertensive rat. Basic Res Cardiol May 2006, 101(3):193-203.
33. Tadokoro K., Nishikimi T., Mori Y., Wang X., Akimoto K., Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. Regul Pept Apr. 15 2003, 112(1-3):71-78.
34. Zhao Y., Bell D., Smith L.R., Zhao L., Devine A.B., McHenry E.M., et al. Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension. J Pharmacol Exp Ther Mar. 2006, 316(3):1269-1281.
35. Bomberger J.M., Parameswaran N., Hall C.S., Aiyar N., Spielman W.S. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem Mar 11. 2005, 280(10):9297-9307.
36. Bomberger J.M., Spielman W.S., Hall C.S., Weinman E.J., Parameswaran N. Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem Jun 24 2005, 280(25):23926-23935.
37. Caron K.M., James L.R., Kim H.S., Knowles J., Uhlir R., Mao L., et al. Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc Natl Acad Sci U S A Mar. 2 2004, 101(9):3106-3111.
38. Caron K.M., James L.R., Kim H.S., Morham S.G., Sequeira Lopez M.L., Gomez R.A., et al. A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci U S A Jun 11 2002, 99(12):8248-8252.
39. Caron K.M., James L.R., Lee G., Kim H.S., Smithies O. Lifelong genetic minipumps. Physiol Genomics Jan. 20 2005, 20(2):203-209.
40. Caron K., Hagaman J., Nishikimi T., Kim H.S., Smithies O. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci U S A Feb. 27 2007, 104(9):3420-3425.
41. Hewitt S.C., Collins J., Grissom S., Deroo B., Korach K.S. Global uterine genomics in vivo: microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. Mol Endocrinol Mar. 2005, 19(3):657-668.
42. Watanabe H., Takahashi E., Kobayashi M., Goto M., Krust A., Chambon P., et al. The estrogen-responsive adrenomedullin and receptor-modifying protein 3 gene identified by DNA microarray analysis are directly regulated by estrogen receptor. J Mol Endocrinol Feb. 2006, 36(1):81-89.
43. Dackor R., Caron K. Mice heterozygous for adrenomedullin exhibit a more extreme inflammatory response to endotoxin-induced septic shock. Peptides Nov. 2007, 28(11):2164-2170.
44. Hagaman J.R., John S., Xu L., Smithies O., Maeda N. An improved technique for tail-cuff blood pressure measurements with dark-tailed mice. Contemp Top Lab Anim Sci Sep. 2005, 44(5):43-46.
45. Dackor R.T., Fritz-Six K., Dunworth W.P., Gibbons C.L., Smithies O., Caron K.M. Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol Apr. 2006, 26(7):2511-2518.
46. Okumura H., Nagaya N., Itoh T., Okano I., Hino J., Mori K., et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation Jan. 20 2004, 109(2):242-248.
47. DeMarco V.G., Habibi J., Whaley-Connell A.T., Schneider R.I., Heller R.L., Bosanquet J.P., et al. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol Jun. 2008, 294(6):H2659-H2668.
48. Murakami S., Kimura H., Kangawa K., Nagaya N. Physiological significance and therapeutic potential of adrenomedullin in pulmonary hypertension. Cardiovasc Hematol Disord Drug Targets Jun. 2006, 6(2):125-132.
49. Ono Y., Okano I., Kojima M., Okada K., Kangawa K. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochem Biophys Res Commun Apr. 29 2000, 271(1):197-202.
50. Qing X., Svaren J., Keith I.M. mRNA expression of novel CGRP1 receptors and their activity-modifying proteins in hypoxic rat lung. Am J Physiol Lung Cell Mol Physiol Mar. 2001, 280(3):L547-L554.
51. Husmann K., Born W., Fischer J.A., Muff R. Three receptor-activity-modifying proteins define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse calcitonin-like receptor in COS-7 cells. Biochem Pharmacol Dec. 1 2003, 66(11):2107-2115.
52. Husmann K., Sexton P.M., Fischer J.A., Born W. Mouse receptor-activity-modifying proteins 1, -2 and ?3: amino acid sequence, expression and function. Mol Cell Endocrinol Apr. 25 2000, 162(1-2):35-43.
53. Nagae T., Mukoyama M., Sugawara A., Mori K., Yahata K., Kasahara M., et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem Biophys Res Commun Apr. 2 2000, 270(1):89-93.
54. Gibbons C., Dackor R., Dunworth W., Fritz-Six K., Caron K.M. Receptor Activity-Modifying Proteins: RAMPing up Adrenomedullin Signaling. Mol Endocrinol Apr. 2007, 21(4):783-796.
55. Nowak W., Parameswaran N., Hall C.S., Aiyar N., Sparks H.V., Spielman W.S. Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity modifying protein-3. Am J Physiol Cell Physiol Jun. 2002, 282(6):C1322-C1331.
56. Bailey R.J., Bradley J.W., Poyner D.R., Rathbone D.L., Hay D.L. Functional characterization of two human receptor activity-modifying protein 3 variants. Peptides Apr. 2010, 31(4):579-584.
57. Ananthakrishnan R., Moe G.W., Goldenthal M.J., Marin-Garcia J. Akt signaling pathway in pacing-induced heart failure. Mol Cell Biochem Jan. 2005, 268(1-2):103-110.
58. Nagoshi T., Matsui T., Aoyama T., Leri A., Anversa P., Li L., et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest Aug. 2005, 115(8):2128-2138.
59. Christopoulos A., Christopoulos G., Morfis M., Udawela M., Laburthe M., Couvineau A., et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem Jan. 31 2003, 278(5):3293-3297.
60. Hay D.L., Poyner D.R., Sexton P.M. GPCR modulation by RAMPs. Pharmacol Ther Jan. 2006, 109(1-2):173-197.
61. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol Jul. 1999, 56(1):235-242.
62. Bouschet T., Martin S., Henley J.M. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci Oct. 15 2005, 118(Pt 20):4709-4720.
63. Harikumar K.G., Simms J., Christopoulos G., Sexton P.M., Miller L.J. Molecular Basis of Association of Receptor Activity-Modifying Protein 3 with the Family B G Protein-Coupled Secretin Receptor. Biochemistry Nov. 13 2009.